Drug Profile


Alternative Names: TR 2515

Latest Information Update: 30 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Developer Cinvestav
  • Class Antihypertensives; Quinazolines; Small molecules; Vasodilators
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 05 Nov 2001 Discontinued-unspecified phase for Hypertension in the European Union
  • 28 Jun 2001 No-Development-Reported for Hypertension in Mexico (Unknown route)
  • 16 Jun 1995 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top